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Abstract
Mucopolysaccharidosis (MPS) IIIB is an inherited lysosomal storage disease caused by the deficiency of the enzyme α-
N-acetylglucosaminidase (NAGLU) required for heparan sulfate (HS) degradation. The defective lysosomal clearance of
undigested HS results in dysfunction of multiple tissues and organs. We recently demonstrated that the murine model
of MPS IIIB develops cardiac disease, valvular abnormalities, and ultimately heart failure. To address the molecular
mechanisms governing cardiac dysfunctions in MPS IIIB, we generated a model of the disease by silencing NAGLU
gene expression in H9C2 rat cardiomyoblasts. NAGLU-depleted H9C2 exhibited accumulation of abnormal lysosomes
and a hypertrophic phenotype. Furthermore, we found the specific activation of the epidermal growth factor receptor
(EGFR), and increased phosphorylation levels of extracellular signal-regulated kinases (ERKs) in NAGLU-depleted H9C2.
The inhibition of either EGFR or ERKs, using the selective inhibitors AG1478 and PD98059, resulted in the reduction of
both lysosomal aberration and hypertrophy in NAGLU-depleted H9C2. We also found increased phosphorylation of c-
Src and a reduction of the hypertrophic response in NAGLU-depleted H9C2 transfected with a dominant-negative c-
Src. However, c-Src phosphorylation remained unaffected by AG1478 treatment, posing c-Src upstream EGFR
activation. Finally, heparin-binding EGF-like growth factor (HB-EGF) protein was found overexpressed in our MPS IIIB
cellular model, and its silencing reduced the hypertrophic response. These results indicate that both c-Src and HB-EGF
contribute to the hypertrophic phenotype of NAGLU-depleted cardiomyoblasts by synergistically activating EGFR and
subsequent signaling, thus suggesting that EGFR pathway inhibition could represent an effective therapeutic
approach for MPS IIIB cardiac disease.
Introduction
Mucopolysaccharidoses (MPSs) are a group of inherited
metabolic diseases, belonging to the class of lysosomal
storage diseases, caused by the deficiency of lysosomal
enzymes required to metabolize glycosaminoglycans
(GAGs)1. The GAG family includes four main subgroups:
hyaluronic acid or hyaluronan (HA), keratan sulfate (KS),
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chondroitin/dermatan sulfate (CS/DS), and heparan sul-
fate (HS)/heparin. With the exception of HA, GAGs are
covalently attached to a core protein, forming the so-
called proteoglycans that are abundantly expressed on the
cell surface and extracellular matrix2. Deficits of GAG
degrading enzymes are responsible for seven different
MPSs (MPS I, II, III, IV, VI, VII, and IX), where the
accumulation of the undegraded GAG results in multiple
organ dysfunctions, with distinct clinical manifestations
depending on the type of the lacking enzyme and the
accumulated substrate1. MPS patients show profound
mental retardation, intractable behavior, skeletal
abnormalities, cardiovascular dysfunction, and death in
the second decade of life1. Cardiac disease has been
commonly observed in MPS patients and contributes to
the early mortality of these patients3–6.
Among MPS subtypes, the MPS IIIB is an autosomal
recessive disorder caused by the deficiency of the α-N-
acetylglucosaminidase (NAGLU) enzyme involved in HS
degradation. The availability of MPS IIIB animal models
and cultured cell systems, including primary fibroblasts
from MPS IIIB patients7,8, has allowed to identify the
defective lysosomal clearance of undigested HS as the
primary cause of organ dysfunctions associated with the
disease. Indeed, the defective lysosomal clearance of HS
leads to the accumulation of abnormal levels of HS not
only within the lysosomes of the cells, but also on the cell
surface and in the extracellular matrix8–10, accounting for
a number of pathologic events affecting various tissues
and organs, including brain, liver, spleen, kidney, and
heart11–14. Both during development and adult life, HS-
associated proteoglycans (HSPGs) play crucial roles in the
regulation of many physiological processes due to their
property to bind and interact with signaling proteins,
morphogens, growth factors, and other critical mole-
cules2,14–17. Besides, the excess of extracellular HS has
been shown to impair fibroblast growth factor 2 (FGF-2)
receptor binding and signaling in cells derived fromMPS I
patients10, and to bind and sequester CXCL12-limiting
hematopoietic migration in the murine model of MPS I9.
As to date no treatments are available for MPS IIIB, a
better understanding of the molecular mechanisms
underlying HS storage defects at cellular level is a man-
datory need to identify new targets for effective ther-
apeutic approaches for MPS IIIB.
Although progressive and severe neurological disorders
are the most relevant clinical manifestations of the MPS
IIIB, cardiac defects including heart failure, arrhythmias,
pulmonary hypertension, and coronary occlusion have also
been reported in affected patients3,18–23. Indeed, we
recently demonstrated that the murine model of MPS IIIB7
develops heart disease, valvular abnormalities, and heart
failure24. However, the mechanisms governing cardiac
dysfunction in MPS IIIB are still poorly investigated. In the
present work, we generated a cellular model of MPS IIIB
cardiac disease by silencing NAGLU gene expression in
H9C2 rat cardiomyoblasts. This cell line has been proved
to represent a relevant model to investigate mechanisms
and consequences of cardiac diseases, including hyper-
trophy, and cardiomyocytes differentiation processes25,26.
NAGLU-silenced H9C2 stable clones showed lysosomal
abnormalities and hypertrophic phenotype, which corre-
lated with epidermal growth factor receptor (EGFR) acti-
vation. Thus, we investigated the EGFR signaling pathway
promoting cell pathology and hypertrophy in NAGLU-
silenced cardiomyoblasts, providing new insights into the
molecular mechanisms by which NAGLU deficiency and
subsequent HS accumulation cause cardiac defects in MPS
IIIB disease.
Results
NAGLU silencing induces lysosomal defects in H9C2
cardiomyoblasts
To explore the molecular mechanisms underlying car-
diac disease in MPS IIIB, we generated a cellular model of
the disease by silencing NAGLU gene expression in
H9C2 cardiomyoblasts through a pool of three DNA
plasmids carrying different shRNAs against NAGLU
mRNA. Silenced clones (H9C2 sh-NAGLU) showed a
significant reduction of NAGLU mRNA and protein
levels compared to that of H9C2 stably transfected with a
non-targeting shRNA (H9C2 sh-CTR) (Fig. 1a, b). The
reduction of NAGLU mRNA and protein levels resulted
in about 70% decrease of NAGLU catalytic activity in the
H9C2 sh-NAGLU compared to that of H9C2 sh-CTR
(Fig. 1c). Since impaired digestion of HS in MPS IIIB
results in the accumulation of the undegraded substrate
and consequent lysosomal enlargement, we investigated
whether NAGLU depletion is sufficient to induce aber-
rant lysosomal accumulation in our cellular model. H9C2
sh-NAGLU showed more abundant and larger intracel-
lular vacuoles compared to H9C2 sh-CTR as detected by
LysoTracker probe staining (Fig. 1d). Consistently, a
significant increase of lysosomal-associated membrane
protein LAMP227 levels were detected in H9C2 sh-
NAGLU compared to H9C2 sh-CTR (Supplementary
Figure S1a). Moreover, by using a fluorescent lectin that
specifically detects sugars and glycoproteins containing β
(1→ 4)-N-acetyl-D-glucosamine and indeed recognizes
HS, we evaluated the distribution of HS in NAGLU-
depleted H9C2. Interestingly, while in H9C2 sh-CTR the
lectin signal was mainly observed in the Golgi apparatus,
in the H9C2 sh-NAGLU clones it was prevalently loca-
lized in intracellular spots at cell periphery and on the
cell surface, indicating a strong accumulation of HS in
these compartments (Fig. 1e).
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Collectively, these data demonstrate that H9C2
sh-NAGLU cardiomyoblasts exhibit the storage
abnormalities observed in MPS IIIB disease, thereby
identifying this model as a valuable tool to investigate
the pathophysiology of MPS IIIB-related cardiac
disease.
Fig. 1 NAGLU silencing in H9C2 cardiomyoblasts causes lysosomal storage defects. a NAGLU mRNA expression levels in control H9C2 stably
transfected with a non-targeting shRNA (H9C2 sh-CTR) and selected NAGLU-depleted H9C2 stable clones (H9C2 sh-NAGLU) as measured by quantitative RT-
PCR analysis. The amount of NAGLU mRNA was normalized with respect to the amount of 18S ribosomal RNA housekeeping gene. The data reported are the
mean ± SD of three independent experiments. *P< 0.05. b NAGLU protein levels in H9C2 sh-CTR and H9C2 sh-NAGLU as measured by western blotting
analysis. To monitor equal loading of protein in the gel lanes, the blot was probed using anti-β-actin antibody. The data reported are the mean± SD of three
independent experiments of equal design. Densitometric analysis of the bands was performed, and the data obtained are reported on the histogram below.
*P< 0.05. c NAGLU enzymatic activity in the extracts from H9C2 sh-CTR and H9C2 sh-NAGLU clones. Cell lysates were assayed for protein content and enzyme
activity (mean ± SD, n= 3) as described in “Materials and methods” section. *P< 0.05. d Representative images of lysosomes labeled with LysoTracker probe in
H9C2 sh-CTR and H9C2 sh-NAGLU. Higher magnification pictures are shown (small panels). Scale bar: 6 μm. In NAGLU-depleted H9C2 more abundant and
larger intracellular vacuoles than control H9C2 are visible. Quantification of LysoTracker staining is the mean ± SD of three independent experiments. *P< 0.05.
e Representative images of HS labeled by lectin-FITC in H9C2 sh-CTR and H9C2 sh-NAGLU. 3D reconstructions of confocal sections along Z-axis are shown
(black and white panels). Scale bar: 10 μm. In NAGLU-depleted H9C2, an increased accumulation of HS in the periphery of the cells and on the cell membrane
is detected compared to control H9C2. Quantification of HS staining is the mean ± SD of three independent experiments. *P< 0.05
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NAGLU silencing induces hypertrophy in H9C2
cardiomyoblasts
We explored whether the lack of NAGLU might cause
cellular hypertrophy as found in NAGLU−/− mice24. To
this aim, we labeled with fluorescent phalloidin the actin
cytoskeleton of NAGLU-depleted and control H9C2
clones. Compared to H9C2 sh-CTR, the H9C2 sh-
NAGLU showed a morphological expansion, typical of
the hypertrophic phenotype, as evaluated by measuring
length, width, and cell area (Fig. 2a). Accordingly, cell
morphology was evaluated also by staining the clones with
Coomassie blue, and H9C2 sh-NAGLU resulted larger in
comparison to control clones (Supplementary Fig-
ure S1b). The hypertrophic phenotype of H9C2 sh-
NAGLU was further confirmed by analyzing the expres-
sion of two markers of hypertrophy: atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP)28.
ANP and BNP mRNA levels were significantly increased
in H9C2 sh-NAGLU compared to control clones (Fig. 2b).
Moreover, cell proliferation was impaired in NAGLU-
depleted H9C2 (Supplementary Figure S1c, d) as well as
the differentiation of H9C2 sh-NAGLU cardiomyoblasts
to cardiomyocytes assessed by measuring the mRNA
levels of the ventricular myosin light chain 2 (MLC2V)
(Supplementary Figure S1e).
These data indicate that NAGLU deficiency leads to
cellular hypertrophy, together with differentiation and
growth defects.
EGFR activation sustains hypertrophy and lysosomal
defects in NAGLU-depleted H9C2 cardiomyoblasts
In order to investigate the signaling pathways activated
by NAGLU silencing in H9C2 cardiomyoblasts, we per-
formed a phospho-receptor tyrosine kinase (RTK) array
on both NAGLU-depleted and control H9C2 clones. Of
49 tested RTKs (Supplementary Table S1), the specific
phosphorylation of EGFR in the H9C2 sh-NAGLU clones
was detected as compared to control clones (Fig. 3a). This
result was confirmed by western blotting analysis of the
phosphorylation levels of EGFR in NAGLU-depleted
H9C2 that resulted to be higher than control clones
(Supplementary Figure S2a). Then, we evaluated EGFR
involvement in the onset of the hypertrophic phenotype
and lysosomal pathology in our cellular model. H9C2 sh-
NAGLU clones treated with the specific EGFR inhibitor
AG147829 showed a significant reduction of ANP and
BNP mRNA levels, as compared to the untreated clones
(Fig. 3b, c). Moreover, AG1478 treatment did not affect
cell size of H9C2 sh-CTR clones (Fig. 4a, upper panels) as
measured by phalloidin staining, whereas it caused a
Fig. 2 NAGLU silencing in H9C2 cardiomyoblasts promotes cellular hypertrophy. a Phalloidin staining of H9C2 sh-CTR and H9C2 sh-NAGLU
actin cytoskeleton. Nuclei were counterstained with DAPI. Scale bar: 10 μm. Cell size enlargement was observed in NAGLU-depleted H9C2 compared
to control H9C2. Quantification of cell size is the mean ± SD of three independent experiments. *P < 0.05. b Expression levels of mRNAs coding for
ANP and BNP hypertrophic mediators in H9C2 sh-CTR and H9C2 sh-NAGLU as measured by quantitative RT-PCR analysis. The amount of ANP and
BNP mRNA was normalized with respect to the amount of 18S ribosomal RNA housekeeping gene. The data reported are the mean ± SD of three
independent experiments. *P < 0.05
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significant reduction of cell dimensions of NAGLU-
depleted H9C2 (Fig. 4a, lower panels). These results
indicate that EGFR inhibition is able to rescue the
hypertrophic phenotype in our MPS IIIB cellular model.
Besides, EGFR was already known to sustain GAG
synthesis and to increase lysosomal pathology in different
MPSs30–32. To establish the EGFR contribution to MPS
IIIB lysosomal disorder in our cellular model, we eval-
uated the lysosomal accumulation in the H9C2 sh-CTR
and H9C2 sh-NAGLU clones treated with the specific
EGFR inhibitor AG1478. AG1478 treatment did not affect
lysosomal compartments in H9C2 sh-CTR clones (Fig. 4b,
upper panels), whereas it caused a significant reduction of
the lysosomal staining in H9C2 sh-NALGU clones
(Fig. 4b, lower panels) as measured by LysoTracker probe.
Consistently, we measured LAMP2 protein levels in H9C2
sh-NAGLU and control clones in the presence of
AG1478. Treatment with the EGFR inhibitor significantly
reduced LAMP2 expression levels in NAGLU-depleted
cardiomyoblasts, whereas it did not influence LAMP2
levels in control clones (Supplementary Figure S2b).
These findings demonstrate that the specific EGFR
inhibition with AG1478 reduces both hypertrophy
and lysosomal defects in our MPS IIIB cell model,
providing more evidence for the involvement of EGFR
activation in the development of cell pathology in MPS
IIIB disease.
EGFR activation promotes ERK1/2 phosphorylation in
NAGLU-depleted H9C2 cardiomyoblasts
The demonstration of the important role of EGFR in the
induction of a hypertrophic response in NAGLU-depleted
cardiomyoblasts prompted us to explore the EGFR signal
transduction pathway contributing to the cardiac
Fig. 3 EGFR activation triggers hypertrophy in NAGLU-silenced H9C2 cardiomyoblasts. a Effect of NAGLU knockdown on RTK activity. p-RTK
array showing the effect of NAGLU silencing on RTK phosphorylation. Cell lysates of H9C2 sh-CTR (left) and H9C2 sh-NAGLU (right) were applied to
p-RTK arrays. The chemiluminescent film images (upper panels) are shown. The blue dots in the lower panels indicate the position of EGFR. b, c
Expression levels of mRNAs coding for ANP (b) and BNP (c) in H9C2 sh-CTR and H9C2 sh-NAGLU both untreated and treated for 90 min with 10 μM of
the EGFR inhibitor AG1478 as measured by quantitative RT-PCR analysis. The amount of ANP and BNP mRNA was normalized with respect to the
amount of 18S ribosomal RNA housekeeping gene. The data reported are the mean ± SD of three independent experiments. *P < 0.05
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phenotype in our MPS IIIB cellular model. Among the
downstream pathways activated by EGFR, phosphoryla-
tion of extracellular signal-regulated kinases (ERK1/2) has
been considered the essential regulator of the hyper-
trophic response33. Therefore, we investigated the phos-
phorylation levels of ERK1 and ERK2 in NAGLU-depleted
rat cardiomyoblasts. Western blot analysis showed a sig-
nificant increase in the phosphorylation levels of both
ERK1 and ERK2 in H9C2 sh-NAGLU compared to con-
trol clones (Fig. 5a). Furthermore, while cell treatment
with the EGFR inhibitor AG1478 had no effect on ERK1/2
phosphorylation levels in control clones, it promoted a
significant reduction of ERK1/2 phosphorylation in H9C2
sh-NAGLU as compared to untreated clones (Fig. 5b),
thus suggesting that ERK1/2 activation in NAGLU-
depleted cardiomyoblasts is mainly EGFR dependent.
Fig. 4 EGFR inhibition reduces the hypertrophic phenotype and lysosomal defects in NAGLU-silenced H9C2 cardiomyoblasts. a
Representative images of actin cytoskeleton stained with phalloidin of H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated for 24 h with
10 μM of AG1478. Scale bars: 10 μm. A significant reduction of cell size was observed in AG1478-treated NAGLU-depleted H9C2 (lower panels), while
no effect was detected in H9C2 sh-CTR clones (upper panels). Quantification of cell size is the mean ± SD of three independent experiments.
*P < 0.05. b Representative images of the lysosomes labeled by LysoTracker probe in H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated
for 24 h with 10 μM of AG1478. Scale bars: 10 μm. In the AG1478-treated H9C2 sh-NAGLU, lysosome staining was significantly reduced compared to
the untreated clones (lower panels), while no effect was detected in H9C2 sh-CTR clones (upper panels). Quantification of LysoTracker staining is the
mean ± SD of three independent experiments. *P < 0.05
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Interestingly, H9C2 sh-NAGLU treatment with
PD9805934,35, a selective inhibitor of the MEK/ERK
pathway, caused a significant reduction of ANP and BNP
mRNA levels (Fig. 5c, d), indicating that ERK1/2 phos-
phorylation is essential for the hypertrophic response in
NAGLU-depleted H9C2. These results were confirmed by
phalloidin staining of both H9C2 sh-CTR and H9C2 sh-
NAGLU exposed to PD98059 inhibitor. PD98059 treat-
ment did not affect cell size of H9C2 sh-CTR clones
(Fig. 6a, upper panels), whereas it caused a significant
reduction of cell dimensions of H9C2 sh-NAGLU clones
(Fig. 6a, lower panels). Furthermore, we asked whether
MEK/ERK pathway inhibition would also rescue the
lysosomal storage phenotype, and we evaluated lysosomal
compartments in PD98059-treated H9C2 sh-CTR and
H9C2 sh-NAGLU. PD98059 treatment did not affect
lysosome staining in H9C2 sh-CTR clones (Fig. 6b, upper
panels), whereas it caused a significant reduction of the
lysosomal storage defect in H9C2 sh-NAGLU clones
(Fig. 6b, lower panels).
Overall, these data indicate that ERK1/2 phosphoryla-
tion mediates EGFR-induced hypertrophic and lysosomal
phenotypes in NAGLU-depleted H9C2.
NAGLU depletion in H9C2 cardiomyoblasts promotes c-Src
activation
Multiple evidence supports a direct link between EGFR
signaling and enhanced Src-family kinase activity36–38.
Here, we evaluated the phosphorylation levels of c-Src in
both H9C2 sh-NAGLU and control clones. The results
obtained showed a significant increase of c-Src phos-
phorylation in NAGLU-depleted H9C2 as compared to
H9C2 sh-CTR (Fig. 7a). However, H9C2 sh-NAGLU
treatment with the EGFR inhibitor AG1478 did not
reduce c-Src phosphorylation levels (Fig. 7b), suggesting
that c-Src phosphorylation represents an upstream event
in EGFR activation. Indeed, the transfection of H9C2 sh-
CTR and H9C2 sh-NAGLU clones with a dominant-
negative (DN) c-Src, while had no effects on H9C2 sh-
CTR clones, caused the reduction of EGFR phosphor-
ylation in the H9C2 sh-NAGLU as detected by western
blotting analysis (Supplementary Figure S3a), indicating
that EGFR phosphorylation in our cellular model of MPS
IIIB might be mediated also by c-Src. Furthermore, the
involvement of c-Src activation in the hypertrophic phe-
notype of NAGLU-depleted cardiomyoblasts was eval-
uated by measuring ANP and BNP mRNA levels in H9C2
sh-NAGLU transfected with DN or (wild-type) WT c-Src.
A significant reduction of ANP and BNP mRNA levels
was observed in H9C2 sh-NAGLU in the presence of DN
c-Src (Fig. 7c, d), whereas ANP and BNP mRNA levels
were strongly increased in the presence of WT c-Src
(Supplementary Figure S3c, d). By contrast, transfection
with DN c-Src or WT c-Src had no effect on either EGFR
phosphorylation or ANP and BNP mRNA levels in H9C2
sh-CTR.
These results indicate that c-Src activation contributes
to the hypertrophic response in NAGLU-depleted cardi-
omyoblasts by activating EGFR and its downstream
signaling.
Heparin-binding EGF-like growth factor (HB-EGF)
upregulation in NAGLU-depleted H9C2
It has been well established that the progressive accu-
mulation of HSPGs on the cell membrane and extra-
cellular matrix contributes to the pathogenesis of MPSs10–
14. The extracellular HSPGs can bind and regulate the
activity of HB-EGF that is a potent EGFR ligand, and
EGFR activation by HB-EGF plays a role in the hyper-
trophic signaling in cardiomyocytes39,40. We investigated
by western blot analysis the expression levels of HB-EGF
in our cellular model, and we detected a significant
increase of HB-EGF protein expression in H9C2 sh-
NAGLU as compared to control clones (Fig. 8a). Fur-
thermore, we tested whether HB-EGF silencing with a
specific siRNA would result in the reduction of the EGFR-
induced hypertrophic response. Upon HB-EGF silencing
in the H9C2 sh-NAGLU (Fig. 8b, c), we detected the
reduction of ANP and BNP mRNA levels compared to the
same cells treated with a scrambled siRNA (Fig. 8c).
Overall, these findings, together with c-Src-dependent
EGFR transactivation, suggest that NAGLU-deficient
cardiomyoblasts develop a hypertrophic phenotype
through a coordinated intracellular and extracellular
EGFR activation induced by c-Src and HB-EGF,
respectively.
Discussion
In this study, we provide the first evidence that abnor-
mal HS accumulation in a MPS IIIB cell model is asso-
ciated with the activation of EGFR signaling resulting in a
hypertrophic phenotype. We first established that
NAGLU silencing in H9C2 rat cardiomyoblasts fully
recapitulates the MPS IIIB lysosomal phenotype and
reproduces the hypertrophic phenotype previously
detected in the cardiac tissues of NAGLU knockout
mice24. These results confirm the reliability of our MPS
IIIB cell model to investigate the molecular events
induced by NAGLU silencing in cardiac cells.
Cardiac hypertrophy is the common response of the
heart to different stimuli, however, prolonged hyper-
trophy increases the risk of heart failure or sudden cardiac
death41,42. Increasing evidence is emerging on the invol-
vement of EGFR pathway activation in the development
of cardiac hypertrophy43,44. Consistently, we found the
specific activation of EGFR in NAGLU-depleted cardio-
myoblasts. Furthermore, we demonstrated that EGFR
inhibition is able to prevent both hypertrophy and
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lysosomal defects in NAGLU-silenced cardiomyoblasts,
suggesting an active role of EGFR in the development of
cell pathology in MPS IIIB disease. The rescue of lyso-
somal phenotype in NAGLU knockdown cardiomyoblasts
following EGFR inhibition might be ascribed to the block
of EGFR signaling cascade regulating the activity of par-
ticular transcription factors involved in GAG biosynth-
esis30–32. Indeed, a therapeutic option for MPSs, called
substrate reduction therapy, is based on the use of gen-
istein, a compound belonging to the family of isoflavones,
Fig. 5 NAGLU silencing promotes ERK1/2 phosphorylation in H9C2 cardiomyoblasts. a ERK1/2 phosphorylation levels in H9C2 sh-CTR and
H9C2 sh-NAGLU as measured by western blotting analysis. To monitor equal loading of protein in the gel lanes, the upper blot was stripped and
reprobed using anti-ERK1/2 antibody. The data reported are the mean ± SD of three independent experiments of equal design. Densitometric
analysis of the bands was performed, and the data obtained are reported on the histogram below. *P < 0.05. b EGFR inhibition reduces ERK1/2
phosphorylation in NAGLU-silenced H9C2. ERK1/2 phosphorylation levels in H9C2 sh-CTR and H9C2 sh-NAGLU both untreated and treated for 90 min
with 10 μM of the EGFR inhibitor AG1478 as measured by western blotting analysis. The upper blot was stripped and reprobed using anti-ERK1/2
antibody. The data reported are the mean ± SD of three independent experiments of equal design. Densitometric analysis of the bands was
performed, and the data obtained are reported on the histogram below. *P < 0.05. c, d Expression levels of mRNAs coding for ANP (c) and BNP (d) in
H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated for 90 min with 50 μM of the MEK/ERK pathway inhibitor PD98059, as measured by
quantitative RT-PCR analysis. The amount of ANP and BNP mRNA was normalized with respect to the amount of 18S ribosomal RNA housekeeping
gene. The data reported are the mean ± SD of three independent experiments. *P < 0.05
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which impairs GAG synthesis by inhibiting EGFR kinase
activity. Genistein treatment, however, only partially
ameliorates the clinical signs of MPS IIIB disease due to
its not exclusive action toward EGFR32,45. These findings
highlight the need for more studies aimed to elucidate the
precise signaling pathways involving EGFR in the cellular
events consequent to the abnormal HS accumulation in
MPS IIIB, including those effects that lead to cardiac
hypertrophy.
The pathogenesis of cardiac hypertrophy involves a
number of complex molecular mechanisms including
Wnt/Frizzled signals, calcineurin, mitofusin-2, tumor
necrosis factor-α, mitogen-activated protein kinases,
Rho kinase, Jun kinases (JNK), poly (ADP-ribose) poly-
merase, transcription factors, oxidative signals, and G
protein-coupled-receptor-associated signaling systems45.
However, the MEK1/ERK1/2 pathway occupies a central
regulatory position in the signaling hierarchy that
Fig. 6 MEK/ERK inhibition reduces cell size enlargement and lysosome abnormalities in H9C2 sh-NAGLU. a Representative images of actin
cytoskeleton stained with phalloidin of H9C2 sh-CTR and H9C2 sh-NAGLU clones, both untreated and treated for 24 h with 50 μM of PD98059. Scale
bars: 10 μm. A significant reduction of cell size was observed in PD98059-treated NAGLU-depleted H9C2 (lower panels), while no effect was detected
in H9C2 sh-CTR clones (upper panels). Quantification of cell size is the mean ± SD of three independent experiments. *P < 0.05. b Representative
images of lysosomes stained with LysoTracker probe in H9C2 sh-CTR and H9C2 sh-NAGLU clones, both untreated and treated for 24 h with 50 μM of
PD98059. 3D reconstructions of confocal sections along Z-axis are shown (black and white panels). Scale bars: 10 μm. In the PD98059-treated H9C2
sh-NAGLU clones, the fluorescence intensity was significantly reduced compared to the untreated clones (lower panels), while no effect was
detected in H9C2 sh-CTR clones (upper panels). Quantification of LysoTracker staining is the mean ± SD of three independent experiments. *P < 0.05
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promotes cardiac hypertrophy33. On the other hand, the
major actors of cardiac hypertrophy, such as ERKs and
JNKs, are activated by EGFR46,47. In agreement with the
above evidence, NAGLU-depleted cardiomyoblasts
showed enhanced ERK1/2 phosphorylation, which was
inhibited by the EGFR inhibitor AG1478. Interestingly,
inhibition of ERK1/2 phosphorylation by the MEK/ERK
inhibitor PD98059 strongly reduced ANP and BNP
mRNA expression levels as well as lysosomal storage
defects in NAGLU-depleted cardiomyoblasts, thus indi-
cating that ERK1/2 phosphorylation induced by EGFR
activation is essential for the lysosomal and hypertrophic
phenotypes detected in our MPS IIIIB cell model.
Many EGFR-mediated cellular functions require
the interaction of the receptor with cellular Src (c-Src),
a membrane-associate tyrosine kinase36,37,48. The
Fig. 7 NAGLU silencing induces c-Src activation in H9C2 cardiomyoblasts. a c-Src phosphorylation levels in H9C2 sh-CTR and H9C2 sh-NAGLU as
measured by western blotting analysis. The upper blot was stripped and reprobed using anti-c-Src antibody. The data reported are the mean ± SD of
three independent experiments of equal design. Densitometric analysis of the bands was performed, and the data obtained are reported on the
histogram below. *P < 0.05. b c-Src phosphorylation levels in H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated for 90 min with 10 μM
the EGFR inhibitor AG1478 as measured by western blotting analysis. The upper blot was stripped and reprobed using anti-c-Src antibody. The data
reported are the mean ± SD of three independent experiments of equal design. Densitometric analysis of the bands was performed, and the data
obtained are reported on the histogram below. *P < 0.05. c, d Expression levels of mRNAs coding for ANP (c) and BNP (d) in H9C2 sh-CTR and
H9C2 sh-NAGLU, both transfected with DN c-Src as measured by quantitative RT-PCR analysis. The amount of ANP and BNP mRNA was normalized
with respect to the amount of 18S ribosomal RNA housekeeping gene. The data reported are the mean ± SD of three independent experiments.
*P < 0.05
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interactions between EGFR and c-Src are bi-directional, in
the sense that c-Src can bind, phosphorylate and activate
EGFR and vice versa. The consequence of this interaction
is an enhanced phosphorylation of specific substrates. For
instance, c-Src-dependent transactivation of EGFR and
Akt/MAPKs is essential for COX-2 upregulation in
endothelial cells38. Furthermore, c-Src activation and its
association with transactivated EGFR have been also
detected in cells stimulated with non-EGF agonists37. In
the present study, we found increased phosphorylation
levels of c-Src in NAGLU-depleted cardiomyoblasts vs.
control clones, while c-Src phosphorylation resulted to be
unaffected by treatment with the EGFR inhibitor AG1478,
suggesting that c-Src phosphorylation represents an
upstream event in EGFR activation. Indeed, EGFR phos-
phorylation levels decreased in H9C2 sh-NAGLU cardi-
omyoblasts transfected with a DN c-Src. Moreover, ANP
and BNP mRNA expression levels resulted to be down-
regulated or upregulated in H9C2 sh-NAGLU cardio-
myoblasts transfected with DN or WT c-Src, respectively.
These findings indicate that, in our MPS IIIB cell model,
c-Src phosphorylation might mediate EGFR activation
with subsequent signaling leading to the hypertrophic
phenotype. Given that c-Src is required for EGFR
internalization and signaling, and that active c-Src may
induce ligand-independent EGFR activation49, inhibition
Fig. 8 Heparin-binding EGF-like growth factor (HB-EGF) upregulation in NAGLU-silenced H9C2 cardiomyoblasts. a HB-EGF protein
expression levels in H9C2 sh-CTR and H9C2 sh-NAGLU as measured by western blotting analysis. The amount of HB-EGF as measured by
densitometry was normalized with respect to the amount of β-actin. The data reported are the mean ± SD of three independent experiments.
*P < 0.05. b HB-EGF protein levels in NAGLU sh-H9C2 transfected with HB-EGF siRNA (siHB-EGF) and with a non-targeting siRNA (siCTR) as measured
by western blotting analysis. To monitor equal loading of protein in the gel lanes, the blot was probed using anti-β-actin antibody (lower blot).
Densitometric analysis of the bands was performed, and the data obtained are reported on the histogram below. The data reported are the mean ±
SD of three independent experiments. *P < 0.05. c Expression levels of mRNAs coding for HB-EGF, ANP, and BNP in H9C2 sh-NAGLU transfected with
HB-EGF siRNA (siHB-EGF) and with a non-targeting siRNA (siCTR) as measured by quantitative RT-PCR analysis. The amount of HB-EGF, ANP, and BNP
mRNAs were normalized with respect to the amount of 18S ribosomal RNA housekeeping gene. The data reported are the mean ± SD of three
independent experiments. *P < 0.05
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of c-Src might also impede EGFR signaling events in
NAGLU defective cells as well as in other cells lacking a
lysosomal enzyme involved in GAG metabolism.
Commonly, EGFR activation may occur either by
transactivation or by binding with ligands such as EGF and
HB-EGF. Transactivation of RTKs by G protein-coupled
receptors (GPCRs) is a common pathway for transmission
of reactive oxygen species-sensitive signals, and interaction
between GPCRs and RTKs may occur either in a ligand-
independent manner involving membrane-associated non-
receptor tyrosine kinases, such as c-Src, or through the
activation of metalloproteases (MMPs), which induce the
release of RTK ligands such as HB-EGF50,51. On the other
hand, it is well established that extracellular HSPGs, whose
accumulation at the cell membrane and extracellular
matrix contributes to the pathogenesis of MPSs, sequester
soluble secreted growth factors and facilitate their binding
to the cognate receptors, thus activating receptor signal-
ing15–17. However, HSPGs also interact with growth fac-
tors that remain anchored to the cell surface via a
transmembrane domain, and especially those belonging to
the EGFR-ligand family which include HB-EGF39. The
proteolytic cleavage of the anchored form of HB-EGF,
namely proHB-EGF, at the extracellular domain gives rise
to the soluble form of HB-EGF. Recently, an important
role for HB-EGF in cardiac heart development, as well as
in cardiac hypertrophy, has been demonstrated40,52,53.
Indeed, angiotensin II-mediated transactivation of EGFR
appears to involve Src-mediated MMP-activated release of
HB-EGF54. In our investigation, we found the upregulation
of HB-EGF in H9C2 sh-NAGLU cardiomyoblasts and the
reduction of the hypertrophic response following HB-EGF
silencing, suggesting that, in our MPS IIIB cell model, HB-
EGF concurs to the activation of EGFR and subsequent
hypertrophic signaling. These findings also suggest that
inhibition of MMPs that activate EGFR by releasing its
ligand HB-EGF might represent a therapeutic strategy for
the treatment of lysosomal storage diseases as MPSs.
However, further studies are needed to address the role of
HB-EGF in MPS IIIB cardiac pathology.
Fig. 9 Schematic diagram depicting the signaling pathways by which NAGLU silencing and subsequent HSPG accumulation promote hypertrophy in
H9C2 cardiomyoblasts through EGFR
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While studies are in progress by the use of the mouse
model of the disease to validate in vivo the results
obtained in NAGLU-silenced cardiomyoblasts, our find-
ings unravel the cellular signaling pathways by which
NAGLU silencing, associated to lysosomal defects and to
an excess of extracellular HSPGs, promotes hypertrophy
through c-Src- and HB-EGF-mediated activation of EGFR
linking to ERK1/2 pathway (Fig. 9). This molecular
mechanism that underlies cell pathology consequent to
the abnormal HS accumulation in MPS IIIB disease is
likely involved in the onset of the cardiac disorders
observed in the affected patients. However, we cannot rule
out that similar mechanisms may be active in other tissues
and organs of MPS IIIB-affected children, and mainly that
they may operate in the pathogenesis of other diseases
where abnormal GAGs accumulate.
In conclusion, our findings provide novel clues for
EGFR pathway targeting-based approaches for MPS IIIB




Mouse anti-diphosphorylated ERK1/2 monoclonal
antibody (M8159, Sigma-Aldrich, St. Louis, MO, USA);
rabbit anti-ERK1/2 polyclonal antibody (V114A, Promega,
Madison, WI, USA); rabbit anti-HB-EGF monoclonal
antibody (ab185555) and rabbit anti-NAGLU monoclonal
antibody (ab214671) (Abcam, Cambridge, MA, USA);
rabbit anti-phospho-Src (Tyr416) polyclonal antibody
(#2101) and rabbit anti-Src (36D10) monoclonal antibody
(#2109) (Cell Signaling Technology, Leiden, the Nether-
lands); mouse anti-β-actin monoclonal antibody (G043,
Abm, Richmond, Canada).
Secondary antibodies
Goat anti-mouse IgG polyclonal antibody conjugated to
horseradish peroxidase (HRP) (sc-2031) and goat anti-
rabbit IgG-HRP polyclonal antibody (sc-3837) (Santa
Cruz Biotechnology, Heidelberg, Germany).
Chemicals
4′,6-diamidino-2-phenylindole (DAPI) (D9542, Sigma-
Aldrich); SDS-PAGE reagents (Bio-Rad Laboratories,
Hercules, CA, USA); PD98059 [2-(2′-amino-3′-methox-
yphenyl)-oxanaphthalen-4-one] (513,000, Calbiochem, La
Jolla, CA, USA); AG1478 [N-(3-chlorophenyl)−6,7-
dimethoxy-4-quinazolinamine], (T4182, Sigma-Aldrich);
puromycin, streptomycin and penicillin, and bovine
serum albumin (BSA) (Sigma-Aldrich); fetal bovine serum
(FBS) (GIBCO, Karlsruhe, Germany); LysoTracker
(L7528, Thermo Fisher Scientific, Fremont, CA, USA),
phalloidin (P1951, Sigma-Aldrich); lectin from Triticum
vulgaris (wheat) FITC conjugate (L4895, Sigma-Aldrich);
IBAfect reagent (7-2005-050, IBA Lifesciences, Goettin-
gen, Germany); 4-methylumbelliferyl-N-acetyl-α-D-glu-
cosaminide (474,500, Calbiochem); Trizol reagent
(15596026, Invitrogen, Carlsbad, CA, USA).
Cell culture and transfections
H9C2 rat cardiomyoblasts (CRL-1446, ATCC, Wesel,
Germany) were cultured in Dulbecco’s minimal essential
medium (DMEM), 1 g/l low glucose, 2 mM L-glutamine, 1
mM sodium pyruvate, supplemented with 10% FBS, 100
units/ml penicillin, and 100 μg/ml streptomycin, at 37 °C
in a humidified 5% CO2 atmosphere.
For stable transfections, H9C2 were plated at a density
of 5× 105 cells/100-mm tissue culture dish in antibiotic-
free DMEM containing 10% FBS, and incubated for 24 h
at 37 °C with 5% CO2. In total, 60–70% confluent cells
were transfected using IBAfect reagent, according to the
manufacturer’s instructions, with a pool of plasmids
codifying for three shRNAs (188A12, 566F3, and 526A3)
targeting NAGLU or with a control plasmid codifying for
a non-targeting shRNA (Open Biosystems, Lafayette, CO,
USA). Forty-eight hours later, transfected H9C2 were
selected in the presence of 0.4 μg/ml of puromycin and
subjected to enzymatic activity assay to identify the stable
NAGLU-silenced clones. Stable clones were grown in
the same culture medium of H9C2 supplemented with
0.4 μg/ml of puromycin for the all experimentation.
For transient transfections, H9C2 clones were plated at
2.5× 105 cells/60-mm tissue culture dish 24 h prior to
transfection. Transfections with plasmid vectors codifying
for c-Src DN and WT, and control vector-GFP55, kindly
provided by Prof. A. Feliciello (University of Naples Fed-
erico II, Naples, Italy), were carried out using IBAfect
reagent according to the manufacturer’s instructions.
After 48 h, transfected H9C2 clones were collected for
molecular analyses.
Transient transfections of H9C2 clones with HB-EGF
siRNA (#AM16708, siRNAID 48748, Thermo Fisher Sci-
entific) and with a non-targeting siRNA (#AM4611,
Thermo Fisher Scientific) were carried out using Lipo-
fectamine RNAiMAX (#13778100, Thermo Fisher Scien-
tific) and 10 nM siRNA, and after 48 h, transfected H9C2
clones were collected for molecular analyses.
Enzyme activity assay
To determine NAGLU enzymatic activity in stable
clones, pellets from 5× 105 cells of each clone were col-
lected, submitted to 10 freeze thaw cycles, and clarified by
centrifugation. Protein concentration of samples was
determined by the Lowry method. NAGLU enzymatic
activity of each clone was measured as described by
Marsh and Fensom using 4-methylumbelliferyl-N-acetyl-
α-D-glucosaminide as fluorogenic substrate56. Enzymatic
activity was normalized for total protein concentration,
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and hydrolysis of 1 nmol of substrate per hour per milli-
gram of protein was defined as one catalytic unit.
Fluorescence microscopy
LysoTracker was used to label lysosomes57. Briefly, live
cell clones grown on a coverslip were incubated with
LysoTracker probe for 1 h at 37 °C, washed with PBS, and
fixed with 4% paraformaldehyde (PFA) solution in PBS.
Phalloidin was used to label actin cytoskeleton. After
washing with PBS, cells were fixed with 4% PFA solution
in PBS, permeabilized with 0.1% Triton X-100, and
stained with 50 μg/ml TRITC-conjugated phalloidin for
30min at room temperature. Subsequently, nuclei were
counterstained with DAPI for 15min.
Lectin was used to label HS. After washing with PBS,
cells were fixed with 4% PFA solution in PBS. After
washing in PBS, cells were permeabilized with 0.1% Triton
X-100 in PBS, and stained with 50 μg/ml fluorescent lectin
conjugate, lectin-FITC, in PBS for 1 h at room
temperature.
After washing with PBS, the coverslips were mounted
with 1:1 PBS/glycerol solution, and observed under a
confocal fluorescence microscope. Images were collected
using a laser-scanning microscope (LSM 510 META, Carl
Zeiss Microimaging, Inc.) equipped with a planapo x63 oil
immersion (NA 1.4) objective lens using the same setting
conditions (e.g., laser power and detector gain) in control
and silenced clones.
Morphometric and image quantitative analyses were
performed with LSM software. In particular, the drawing
tool was used to measure the relative dimensions and cell
area. Fluorescence intensity of random chosen areas of
same size was measured58.
Quantitative RT-PCR
Total RNA from H9C2 stable clones was extracted using
Trizol reagent following the manufacturer’s instruction.
Five hundred nanograms of RNA were reverse transcribed
for cDNA synthesis with Iscript RT-PCR system (Bio-rad
Laboratories). Reverse transcription of the RNAs was fol-
lowed by quantitative real-time PCR (Q-PCR) performed
with the SYBR Green real-time PCR master mix kit (FS
Universal SYBR Green MasterRox/Roche Applied Science)
as previously described59. The reactions were visualized by
SYBR Green analysis (Applied Biosystem Inc, Foster City,
CA, USA) on StepOne instrument (Applied Biosystem).








GGC-3′; Reverse: 5′-CCCAGGCCAGGAA GGCAG
G-3′; S18-Forward: 5′-AAACGGCTACCACATCCAAG-
3′; Reverse: 5′-CCTCCAAT GGATCCTCGTTAA-3′. All
standards and samples were assayed in triplicate. Thermal
cycling was initiated with an initial denaturation at 95 °C
for 5min. After this initial step, 40 cycles of PCR were
performed. Each PCR cycle consisted of heating at 95 °C
for 30 s for melting, 55 °C for 30 s for annealing, and 72 °C
for 30 s for the extension. To calculate the relative
expression levels, we used the 2-ΔΔCT method 60.
Western blotting
Cells, grown to sub-confluence in standard medium,
were harvested in lysis buffer (50 mM Tris pH 7.5, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1%
Triton X-100, 1 mM β-glycerophosphate, 1 mM phe-
nylmethylsulfonyl fluoride, protease inhibitor cocktail
tablet, 1 mM sodium orthovanadate, and 2.5 mM sodium
pyrophosphate)61. The lysates were incubated for 30 min
on ice, and supernatants were collected and centrifuged
for 30 min at 14,000× g. Protein concentration was esti-
mated by Bradford assay, and 25 or 50 μg/lane of total
proteins were separated on SDS gels and transferred to
nitrocellulose membranes62. Membranes were treated
with a blocking buffer (25 mM Tris, pH 7.4, 200mM
NaCl, 0.5% Triton X-100) containing 5% non-fat pow-
dered milk for 1 h at room temperature63. Incubation with
the primary antibody was carried out overnight at 4 °C.
After washings, membranes were incubated with the
HRP-conjugated secondary antibody for 1 h at room
temperature. Following further washings of the mem-
branes, chemiluminescence was generated by enhanced
chemiluminescence (ECL) kit (Amesharm, Little Chal-
font, UK). Densitometric analyses were performed using
the NIH Image software (Bethesda, MD, USA).
Phospho-receptor tyrosine kinase (phospho-RTK) array
The Phospho-RTK Array (ARY001B, R&D Systems,
Minneapolis, MN, USA) is a rapid and sensitive tool to
detect changes in phosphorylation between samples. The
array, which allows the screening of 49 different phos-
phorylated RTKs, was performed as here briefly described.
All reagents and samples were prepared according to the
manufacturer’s instructions. An aliquot of 2 ml of Array
Buffer 1 was pipetted into each well of the 4-well multi-
dish as a blocking buffer; each array was placed into each
well of the 4-well multi-dish and incubated for 1 h at
room temperature on a rocking platform shaker. Samples
were prepared by diluting the desired quantity (50 μg of
proteins) of cell lysates to a final volume of 1.5 ml with
Array Buffer 1, and incubated overnight at 2–8 °C on a
rocking platform shaker pre-blocked membrane. Each
array was carefully placed into individual plastic con-
tainers with 2 ml of 1×Wash Buffer, and the 4-well multi-
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dish was rinsed with deionized or distilled water, and
dried thoroughly. Each array was washed with 1× Wash
Buffer for 10min on a rocking platform shaker for three
times. The anti-phospho-tyrosine-HRP detection anti-
body was finally diluted in 1× Array Buffer 2, and added
to each array for 2 h at room temperature on a rocking
platform shaker. Each array was washed three times with
2 ml of 1× Wash Buffer for 10min on a rocking platform
shaker. Membranes were incubated with 1 ml of the
prepared Chemi Reagent Mix for 1 min. Membranes were
exposed with an autoradiography film cassette to an X-ray
film for 1–10 min. For the data analysis, the positive signal
seen on developed film was identified by placing the
transparency overlay template on the array image and
aligning it with the pairs of reference spots in the three
corners of each array. Reference spots are included to
align the transparency overlay template and to demon-
strate that the array has been incubated with anti-
phospho-tyrosine-HRP during the assay procedure.
Statistical analysis
Data reported are expressed as the mean± SD of at least
three separate experiments. Statistical significance was
determined by Student’s t test. A value of P< 0.05 was
considered to be statistically significant.
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